Strategy for overcoming drug resistance of leukemic stem cells by using micro-RNA targeted for telomerase
Project/Area Number |
22501053
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Clinical oncology
|
Research Institution | Tokyo Women's Medical University |
Principal Investigator |
YAMADA Osamu 東京女子医科大学, 医学部, 准教授 (30167712)
|
Project Period (FY) |
2010 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | テロメレース / マイクロ RNA / 薬剤耐性 / 白血病幹細胞 / MDR1 / メチレーション / STAT5 / 分子標的治療 / マイクロRNA |
Research Abstract |
The object of our experiment is to know microRNA regulating telomerase expression. Together with the results of methylation analysis of drug resistant cells, we tried to develop therapeutic strategies for overcoming drug resistance of cancer stem cells. As a result, methylation level of both telomerase and MDR1 promoter lesion was stable during acquisition of drug resistance. Instead, increased expression of telomerase and MDR1 protein which was caused through the activation of transcription factor STAT5, was observed.
|
Report
(4 results)
Research Products
(39 results)
-
[Journal Article] Emergence of a Variant BCR-ABL Translocation, t(9;22;21), in a Patient with the JAK2V617F Mutation: Evidence for Secondary Acquisition of BCR-ABL in the JAK2V617F Clone2013
Author(s)
Yamada O, Mahfoudhi E, Plo I, Ozaki, K, Nakatake M, Akiyama M, Yamada H, Kawauchi K and Vainchenker W
-
Journal Title
Journal of Clinical Oncology
Volume: (in press)
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-